GenPro offers expert consulting services on complex statistical issues encountered during study design or analysis. We provide guidance in incorporating and analysing the effectiveness of statistical methodologies in clinical trials with a great deal of expertise in adaptive designs and Bayesian analysis. Our biostatisticians possess the experience and critical thinking to assist clients. They are industry experts in several statistical areas including adaptive design, personalised medicine, Bayesian analysis and non-inferiority approaches with extensive experience in several indications. Genpro team has been working for more than 15 years in NDA/ BLA/PMA submission and interacting with FDA/ EMEA and PMDA and actively collaborate with academic, industry and FDA working groups. We are well versed with CDISC data standards and electronic submission standards to deliver high quality, dependable analyses.
Design of Statistical Experiments.
To reach the objective an experiment should be designed appropriately.We the statisticians of Genpro helps to ensure that the experiments are designed in the best way to meet the objective of the study which will help to reduce the repetition of experiments.
Adaptive methodologies include Seamless Phase 2/3 Designs,Group Sequential Designs, Adaptive Dose Response design etc.
GenPro brings the expertise of designing and analysis of different types of adaptive methods to implement the most innovative clinical trials. Some of the adaptive methodologies include Seamless Phase 2/3 Designs,Group Sequential Designs , Blinded and Unblinded Sample Size Re-estimation,Adaptive Dose Response design,Futility Stopping Designs,Dose Finding Designs and Bayesian Adaptive Designs.
Study Objectives, Expected Outcomes, Sample Size and more.
Genpro biostatisticians have a great deal of experience in writing the study objective, the assumptions regarding the expected outcomes , the sample size required and the specific statistical techniques that will be used to evaluate the results are included.
Identify the primary and secondary study endpoints.
We engage in the planning stage of a clinical trial itself to identify endpoints, formulate testable hypothesis and to confirm the parameters of interest.
Bayesian and Bayesian Adaptive Designs, used meta-analytic and modeling approaches.
GenPro staff has extensive experience in the area of Bayesian Designs. They have been instrumental in designing several Bayesian and Bayesian Adaptive Designs, used meta-analytic and modeling approaches to reduce the sample size and led several discussions at FDA and EMA. They have been responsible for several PMA submissions using the Bayesian approach.
Enrichment strategies and study design options for decreasing heterogenity, prognostic enrichment and predictive enrichment. The decision to use an enrichment design is largely left to the sponsor of the investigation, but like the entire research and clinical communities, FDA is very interested in: Targeting treatments to the people who can benefit from them (i.e., individualization). The ability of the study to demonstrate effectiveness, which can be enhanced by using an enriched population. Describing study findings properly in drug labeling.
Interim assessments during the course of the study.
Interim analysis is performed to assess quality of the data collected, or treatment effects during the course of the study. Genpro Statistician’s has the expertise to understand the requirements of the study,development of interim analysis plan and designing relevant outputs.
Randomisation Center in charge of creating the randomisation lists and breaking the blind. Randomization is considered as an essential tool when testing for efficacy of treatment in a clinical trial. Randomized trials are gold standard of study designs since the randomized trials have the ability to avoid bias.
To read more about Genpro’s unique Bayesian Adaptations, PK/PD Analysis, and offshore Randomization support, click here.
We would love to hear from you !....